Physician profile
Salil Dua
NPI 1780658625
$7,274.44
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,727 · 2020: $1,086 · 2021: $4,387 · 2023: $74.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $74.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $74.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,031.44 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $829.43 | 2019-2021 | |
| Glaxosmithkline, LLC. | $491.15 | 2019-2021 | |
| Lilly USA, LLC | $444.73 | 2019-2021 | |
| Allergan, INC. | $337.65 | 2019-2020 | |
| Pfizer INC. | $274.19 | 2019-2021 | |
| Amgen INC. | $146.62 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $139.75 | 2019-2020 | |
| Mdd US Operations, LLC | $124.99 | 2019 | |
| Daiichi Sankyo INC. | $116.95 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.41 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $54.97 | 2020-2021 | |
| Novo Nordisk INC | $42.38 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.18 | 2021 | |
| Vanda Pharmaceuticals INC. | $37.53 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $30.82 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.64 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.00 | 2021 | |
| Corcept Therapeutics | $11.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salil Dua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.